Industry news that matters to you.  Learn more

New Biomarker Predicts Alzheimer’s Disease and Link to Diabetes

An enzyme found in the fluid around the brain and spine is giving researchers a snapshot of what happens inside the minds of Alzheimer’s patients and how that relates to cognitive decline.

Iowa State University researchers say higher levels of the enzyme, autotaxin, significantly predict memory impairment and Type 2 diabetes. Just a one-point difference in autotaxin levels – for example, going from a level of two to a three – is equal to a 3.5 to 5 times increase in the odds of being diagnosed with some form of memory loss, said Auriel Willette, an assistant professor of food science and human nutrition at Iowa State.

Immunovia Announces the Start of PANFAM-1, the Largest Ever Prospective Multi-center Clinical Study for Early Detection of Pancreatic Cancer

Immunovia AB today announced the start of PANFAM-1, a multicenter prospective validation study for the early diagnosis in familiar pancreatic cancer (FPC) high risk individuals. The first site now collecting blood samples is the Spanish research center Ramon y Cajal Institute for Health Research (IRYCIS) in Madrid. Designed to validate Immunovia ́s blood test, IMMrayTM PanCan-d, the study will run for three years across sites in both the US and Europe offering FPC screening programs.

Menarini-Silicon Biosystems to Acquire CELLSEARCH CTC System

Menarini-Silicon Biosystems today announced they have signed an agreement to purchase all the assets and relevant business related to the CELLSEARCH® Circulating Tumor Cell (CTC) system from Janssen Diagnostics, LLC. CELLSEARCH® is used to help manage patients with metastatic breast, prostate, and colorectal cancers. It is the only FDA-cleared CTC test, and has also been approved by China’s FDA for use in monitoring breast cancer patients. Financial details were not disclosed.

Habit Pioneers Personalized Nutrition Category

Habit, a new company that is at the intersection of nutrition, technology and food delivery, unveiled plans to launch a complete personalized nutrition solution for people who want to harness the transformative power of food to improve their lives.

Unlike generic, one-size-fits-all eating fads, which may work for one person but not another, Habit develops nutrition recommendations based on an individual’s unique biology, metabolism and personal goals. Habit takes the guesswork and confusion out of what to eat by creating a personal nutrition blueprint for each individual. Then it helps one reach their health goals by delivering fresh, personalized meals to one’s doorstep and supporting through one-on-one wellness and nutrition coaching.

Annai Systems Provides STARPlatform NGS Data Management Solution to Global Consortium Focused on Tumor Research

Annai Systems, a leading genomic data solutions company, recently announced it will provide its STARPlatform next-generation sequencing data management solution to the Glioma Longitudinal AnalySiS (GLASS) consortium. The GLASS consortium consists of neuropathologists, clinicians, scientists, and bioinformaticians from leading institutions across the globe. Annai Systems’ STARPlatform will enable GLASS to manage whole exome and genome sequencing data across multiple research centers.